Editorial
Skeletal dysplasias: New medical treatments
Displasias esqueléticas: nuevos tratamientos médicos
a Servicio de Pediatría, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
b Servicio de Endocrinología, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
c Departamento de Pediatría, Universidad Autónoma de Madrid, Madrid, Spain
d CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
Read
9195
Timeswas read the article
2685
Total PDF
6510
Total HTML
Share statistics
array:23 [ "pii" => "S2341287916300795" "issn" => "23412879" "doi" => "10.1016/j.anpede.2016.03.002" "estado" => "S300" "fechaPublicacion" => "2016-07-01" "aid" => "2085" "copyright" => "Asociación Española de Pediatría" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "An Pediatr (Barc). 2016;85:1-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2731 "formatos" => array:3 [ "EPUB" => 183 "HTML" => 1879 "PDF" => 669 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1695403316301539" "issn" => "16954033" "doi" => "10.1016/j.anpedi.2016.03.015" "estado" => "S300" "fechaPublicacion" => "2016-07-01" "aid" => "2085" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "An Pediatr (Barc). 2016;85:1-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 17069 "formatos" => array:3 [ "EPUB" => 149 "HTML" => 15552 "PDF" => 1368 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Displasias esqueléticas: nuevos tratamientos médicos" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1" "paginaFinal" => "3" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Skeletal dysplasias: New medical treatments" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jesús Argente, Gabriel Á. Martos Moreno" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Jesús" "apellidos" => "Argente" ] 1 => array:2 [ "nombre" => "Gabriel Á." "apellidos" => "Martos Moreno" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2341287916300795" "doi" => "10.1016/j.anpede.2016.03.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287916300795?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403316301539?idApp=UINPBA00005H" "url" => "/16954033/0000008500000001/v1_201606240034/S1695403316301539/v1_201606240034/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2341287916300825" "issn" => "23412879" "doi" => "10.1016/j.anpede.2015.07.038" "estado" => "S300" "fechaPublicacion" => "2016-07-01" "aid" => "1936" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2016;85:4-12" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2868 "formatos" => array:3 [ "EPUB" => 162 "HTML" => 2184 "PDF" => 522 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "The challenge of administering anti-tuberculosis treatment in infants and pre-school children. pTBred Magistral Project" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "4" "paginaFinal" => "12" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "El reto de la administración de antituberculosos en lactantes y preescolares. Proyecto Magistral de pTBred" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1479 "Ancho" => 1555 "Tamanyo" => 91588 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Number of patients with latent tuberculosis infection or active tuberculosis disease that received care at the surveyed institutions in 2014.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Roi Piñeiro Pérez, Begoña Santiago García, Cecilia M. Fernández-Llamazares, Fernando Baquero Artigao, Antoni Noguera Julian, María José Mellado Peña" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Roi" "apellidos" => "Piñeiro Pérez" ] 1 => array:2 [ "nombre" => "Begoña" "apellidos" => "Santiago García" ] 2 => array:2 [ "nombre" => "Cecilia M." "apellidos" => "Fernández-Llamazares" ] 3 => array:2 [ "nombre" => "Fernando" "apellidos" => "Baquero Artigao" ] 4 => array:2 [ "nombre" => "Antoni" "apellidos" => "Noguera Julian" ] 5 => array:2 [ "nombre" => "María José" "apellidos" => "Mellado Peña" ] 6 => array:1 [ "colaborador" => "representación de pTBred (Red Española de Estudio de Tuberculosis Pediátrica)" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1695403315003318" "doi" => "10.1016/j.anpedi.2015.07.027" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403315003318?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287916300825?idApp=UINPBA00005H" "url" => "/23412879/0000008500000001/v1_201606240044/S2341287916300825/v1_201606240044/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Skeletal dysplasias: New medical treatments" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1" "paginaFinal" => "3" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Jesús Argente, Gabriel Á. Martos Moreno" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Jesús" "apellidos" => "Argente" "email" => array:1 [ 0 => "jesus.argente@uam.es" ] "referencia" => array:5 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 4 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Gabriel Á." "apellidos" => "Martos Moreno" "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Servicio de Pediatría, Hospital Infantil Universitario Niño Jesús, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Endocrinología, Hospital Infantil Universitario Niño Jesús, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Departamento de Pediatría, Universidad Autónoma de Madrid, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Displasias esqueléticas: nuevos tratamientos médicos" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Skeletal dysplasias, a broad and heterogeneous group of genetic diseases that manifest with growth abnormalities associated with alterations in the development and differentiation of bone and cartilage, constitute one of the most important groups of diseases requiring care from specialised paediatric practitioners in the different paediatric age groups.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Two developments in the traditional fields of medicine and radiology have been crucial in improving the diagnosis of these diseases: the spectacular advances in methods for detecting monogenic disease, and the introduction of new therapeutic molecules, which are still undergoing international controlled clinical trials but have shown promising results.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The most recent revision on the nosology and classification of skeletal dysplasias<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> showed that while the number of diseases has decreased from 456 to 436, the number of groups has increased from 40 to 42 and the number of involved genes from 226 to 364 compared to the previous 2011 revision.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Although each skeletal dysplasia is rare, their collective birth incidence is estimated at 1:4000 to 1:5000 live births. Thus, these congenital anomalies are identified in 5% of newborns, even though the actual incidence is probably higher.</p><p id="par0025" class="elsevierStylePara elsevierViewall">When presented with a patient that may have a skeletal dysplasia, the following must be performed: (a) Clinical evaluation: assessment of disproportionate short stature (prenatal, neonatal or postnatal), family history (mean parental height and other possible cases of stature), family tree (comprising at least three generations), weight, length and head circumference at birth, growth rate; (b) Physical examination: length or height, weight, head circumference, upper to lower segment ratio, sitting height and arm span (description of the eventual shortening of the extremities: rhizomelic, mesomelic or acromelic); cranial characteristics, mediofacial hypoplasia, nasal shape, presence of blue sclera, cleft palate, micrognathia, dental abnormalities, pectus excavatum, pectus carinatum, lordosis, scoliosis, genu varum/valgum, brachydactyly. The characteristics of nails, hair and skin should be evaluated, along with potential hearing and/or vision abnormalities and cognitive impairment, and kidney, liver and cardiac function and general laboratory tests should be performed; (c) Radiological assessment: the radiological patterns may include diaphyseal, metaphyseal, epiphyseal, spondylar or mixed abnormalities. The radiological investigation should include radiographs of the skull, upper extremities, lower extremities, thorax, hips and spine, and an assessment of bone maturation and mineral density; and (d) Genetic testing: gene sequencing, gene panel analysis, whole-exome sequencing and whole-genome sequencing. Taking cost-effectiveness into account, in cases of skeletal dysplasia the analysis of specific sets of genes using panels may be the most appropriate option if the dysplasia has been thoroughly evaluated and the diagnosis has been narrowed down, while whole-exome sequencing may offer a better yield otherwise. As our knowledge grows in the future, we will be able to provide more specific information.</p><p id="par0030" class="elsevierStylePara elsevierViewall">Given the large number of disease classifications and their considerable genetic heterogeneity, we face great challenges to advance in their diagnosis. The fact that different diseases may share underlying mechanisms has fuelled the interest in finding new therapeutic targets.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Current situation in the development of therapeutic targets for the treatment of some skeletal dysplasias</span><p id="par0035" class="elsevierStylePara elsevierViewall">Achondroplasia is the most prevalent skeletal dysplasia. In achondroplasia, mutations in the <span class="elsevierStyleItalic">FGFR3</span> gene (MIM 134934) lead to abnormalities in chondrocyte proliferation and terminal differentiation and in the synthesis of the extracellular matrix in growth plate cartilage. The <span class="elsevierStyleItalic">NPR2</span> gene encodes the natriuretic peptide receptor B (NPR-B), which acts as an endogenous receptor for C-type natriuretic peptide (CNP). C-type natriuretic peptide antagonises <span class="elsevierStyleItalic">FGFR3</span> downstream signalling by inhibiting the MAPK pathway. Overexpression of CNP in chondrocytes prevents bone shortening in a mouse model of achondroplasia, suggesting that CNP could be an effective treatment for this disease.</p><p id="par0040" class="elsevierStylePara elsevierViewall">BioMarin Pharmaceutical Incorporated has developed a CNP analogue that is 39 amino acids long for subcutaneous administration (BMN-111). This drug offers an extended half-life due to its resistance to neutral endopeptidase digestion, making it possible to administer it once a day through the subcutaneous route. A multicentre, multinational clinical trial is currently underway and could be completed in 2017 (ClinicalTrials.gov identifier: NCT02055157). A recent review analysed the different therapeutic options for achondroplasia, from surgery to trials involving growth hormone to future treatments, including the CNP analogue.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> The 39-amino acid long CNP analogue is raising hopes of finding a treatment that could improve bone structure in patients with achondroplasia and possibly hypochondroplasia.</p><p id="par0045" class="elsevierStylePara elsevierViewall">The initial results of the use of KRN23 in patients with X-linked dominant hypophosphataemic rickets (XLH) have been published recently.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> KRN23 is a monoclonal antibody that inhibits the activity of fibroblast growth factor 23 (FGF23), which mediates the deficient phosphate reabsorption from the kidney and the abnormal vitamin D metabolism. The results of the trial show a beneficial effect, with increased thresholds of phosphate reabsorption and increased serum levels of phosphate and calcitriol in adults. A clinical trial in children with XLH aged 5–12 years is underway (ClinicalTrials.gov identifier: NCT02163577) and will be expanded to include patients aged 1–5 years in Phase III.</p><p id="par0050" class="elsevierStylePara elsevierViewall">When it comes to hypophosphatasia due to congenital deficiency of tissue-nonspecific alkaline phosphatase (AP), an ongoing international clinical trial is evaluating the efficacy and safety of the use of asfotase alfa (recombinant alkaline phosphatase) in children aged less than 5 years with the most severe forms of the disease (perinatal/infancy) (ClinicalTrials.gov identifier: NCT01176266). This experimental treatment is relevant due to the systemic scope of this disease, with severe involvement of other organs and systems in addition to the skeleton, and an exceedingly high mortality in the most severe early-onset forms. Favourable outcomes of this treatment have already been reported,<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> with improvements in radiological findings, lung function and physical ability in infants and young children with potentially fatal forms of hypophosphatasia, and long-lasting effects in the recovery of growth, strength, agility and motor functioning resulting from the skeletal improvement experienced after sustained treatment over three years with this drug, which has been recently approved by the European Medicines Agency (EMA).</p><p id="par0055" class="elsevierStylePara elsevierViewall">A single gene (<span class="elsevierStyleItalic">TNSALP</span> or <span class="elsevierStyleItalic">ALPL</span>, 1p36.12) encodes the liver/bone/kidney AP. The more than 300 mutations on the <span class="elsevierStyleItalic">ALPL</span> gene known to date determine the development of the different clinical phenotypes of hypophosphatasia (<a id="intr0010" class="elsevierStyleInterRef" href="http://www.sesep.uvsq.fr/03_hypo_mutations.php">http://www.sesep.uvsq.fr/03_hypo_mutations.php</a>).</p><p id="par0060" class="elsevierStylePara elsevierViewall">Denosumab, a monoclonal antibody that inhibits RANKL, is a potent and effective treatment for pathological processes involving bone resorption, such as osteoporosis and different types of bone tumours and metastases (for which its use is already indicated in adults). In children, it has been used off label to treat malignant hypercalcaemia and fibrous dysplasia.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> An ongoing international multicentre clinical trial is evaluating its use in children aged 5–10 years with moderate to severe osteogenesis imperfecta (ClinicalTrials.gov identifier: NCT01799798). At present, the use of biphosphonates to prevent fractures in these patients is questioned to some degree.</p><p id="par0065" class="elsevierStylePara elsevierViewall">Another group of skeletal dysplasias in which there has been considerable progress in the development of specific therapies is the mucopolysaccharidose (group 27 in the 2015 nosology classification).<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">At present, the FDA and the EMA authorise enzyme-replacement therapy for mucopolysaccharidosis type I (laronidase), type II (idursulfase), type IV (elosulfase alfa) and type VI (galsulfase); while intrathecal therapy for types I, II, and IIIA is currently undergoing clinical trials (due to the inability of these molecules to cross the blood-brain barrier).<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">In addition to enzyme-replacement therapy, haematopoietic stem cell transplantation is the gold standard for treatment of severe forms of mucopolysaccharidosis type I, and may be useful in severe forms of type II and in types VI and VII. Gene therapy approaches involving direct delivery to the brain or autologous transplants of previously modified cells for children with mucopolysaccharidosis subtype IIIA are currently in the clinical trial phase.</p><p id="par0080" class="elsevierStylePara elsevierViewall">In conclusion, the paediatrician must take on new diagnostic challenges for the routine evaluation of the multiple skeletal dysplasias through an organised approach and incorporating emerging genetic testing methods in everyday practice. An accurate diagnosis will allow the application of new treatments that are starting to show highly promising results in specific diseases. We welcome these diagnostic and therapeutic advancements that, thanks to research, can improve the symptoms and quality of life of our children.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Current situation in the development of therapeutic targets for the treatment of some skeletal dysplasias" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Argente J, Martos Moreno GÁ. Displasias esqueléticas: nuevos tratamientos médicos. An Pediatr (Barc). 2016;85:1–3.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nosology and classification of genetic skeletal disorders: 2015 revision" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Bonafe" 1 => "V. Cormier-Daire" 2 => "C. Hall" 3 => "R. Lachman" 4 => "G. Mortier" 5 => "S. Mundlos" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Am J Med Genet A" "fecha" => "2015" "volumen" => "167" "paginaInicial" => "2869" "paginaFinal" => "2892" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Achondroplasia: current options and future perspective" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "H. Bouali" 1 => "H. Latrech" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Pediatr Endocrinol Rev" "fecha" => "2015" "volumen" => "12" "paginaInicial" => "388" "paginaFinal" => "395" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26182483" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "«El hueso» en movimiento" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G.Á. Martos-Moreno" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Esp Endocrinol Pediatr" "fecha" => "2014" "volumen" => "5" "paginaInicial" => "5" "paginaFinal" => "8" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.P. Whyte" 1 => "C. Rockman-Greenberg" 2 => "K. Ozono" 3 => "R. Riese" 4 => "S. Moseley" 5 => "A. Melian" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/jc.2015-3462" "Revista" => array:6 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2016" "volumen" => "101" "paginaInicial" => "334" "paginaFinal" => "342" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26529632" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Introducción a las mucopolisacaridosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Del Toro Riera" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:6 [ "titulo" => "Guía para el manejo de las MPS" "fecha" => "2015" "paginaInicial" => "7" "paginaFinal" => "18" "editorial" => "Ergón" "editorialLocalizacion" => "Madrid" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23412879/0000008500000001/v1_201606240044/S2341287916300795/v1_201606240044/en/main.assets" "Apartado" => array:4 [ "identificador" => "25501" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/23412879/0000008500000001/v1_201606240044/S2341287916300795/v1_201606240044/en/main.pdf?idApp=UINPBA00005H&text.app=https://analesdepediatria.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287916300795?idApp=UINPBA00005H" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 18 | 13 | 31 |
| 2024 October | 64 | 57 | 121 |
| 2024 September | 93 | 35 | 128 |
| 2024 August | 116 | 71 | 187 |
| 2024 July | 123 | 36 | 159 |
| 2024 June | 101 | 41 | 142 |
| 2024 May | 99 | 52 | 151 |
| 2024 April | 93 | 37 | 130 |
| 2024 March | 81 | 30 | 111 |
| 2024 February | 106 | 29 | 135 |
| 2024 January | 102 | 28 | 130 |
| 2023 December | 123 | 29 | 152 |
| 2023 November | 110 | 31 | 141 |
| 2023 October | 89 | 34 | 123 |
| 2023 September | 74 | 28 | 102 |
| 2023 August | 73 | 22 | 95 |
| 2023 July | 80 | 42 | 122 |
| 2023 June | 67 | 38 | 105 |
| 2023 May | 74 | 31 | 105 |
| 2023 April | 43 | 18 | 61 |
| 2023 March | 63 | 23 | 86 |
| 2023 February | 63 | 27 | 90 |
| 2023 January | 49 | 25 | 74 |
| 2022 December | 73 | 21 | 94 |
| 2022 November | 72 | 49 | 121 |
| 2022 October | 62 | 52 | 114 |
| 2022 September | 48 | 36 | 84 |
| 2022 August | 68 | 44 | 112 |
| 2022 July | 36 | 29 | 65 |
| 2022 June | 76 | 35 | 111 |
| 2022 May | 59 | 29 | 88 |
| 2022 April | 89 | 40 | 129 |
| 2022 March | 125 | 51 | 176 |
| 2022 February | 118 | 47 | 165 |
| 2022 January | 109 | 35 | 144 |
| 2021 December | 87 | 44 | 131 |
| 2021 November | 83 | 48 | 131 |
| 2021 October | 84 | 63 | 147 |
| 2021 September | 58 | 39 | 97 |
| 2021 August | 65 | 50 | 115 |
| 2021 July | 47 | 20 | 67 |
| 2021 June | 63 | 51 | 114 |
| 2021 May | 62 | 37 | 99 |
| 2021 April | 242 | 91 | 333 |
| 2021 March | 110 | 47 | 157 |
| 2021 February | 149 | 22 | 171 |
| 2021 January | 104 | 17 | 121 |
| 2020 December | 66 | 36 | 102 |
| 2020 November | 68 | 26 | 94 |
| 2020 October | 55 | 25 | 80 |
| 2020 September | 56 | 31 | 87 |
| 2020 August | 49 | 9 | 58 |
| 2020 July | 63 | 22 | 85 |
| 2020 June | 63 | 16 | 79 |
| 2020 May | 60 | 28 | 88 |
| 2020 April | 67 | 15 | 82 |
| 2020 March | 64 | 20 | 84 |
| 2020 February | 62 | 29 | 91 |
| 2020 January | 77 | 25 | 102 |
| 2019 December | 63 | 21 | 84 |
| 2019 November | 57 | 21 | 78 |
| 2019 October | 71 | 16 | 87 |
| 2019 September | 48 | 21 | 69 |
| 2019 August | 57 | 20 | 77 |
| 2019 July | 61 | 23 | 84 |
| 2019 June | 103 | 31 | 134 |
| 2019 May | 135 | 29 | 164 |
| 2019 April | 91 | 41 | 132 |
| 2019 March | 51 | 21 | 72 |
| 2019 February | 58 | 12 | 70 |
| 2019 January | 50 | 23 | 73 |
| 2018 December | 61 | 32 | 93 |
| 2018 November | 80 | 36 | 116 |
| 2018 October | 88 | 38 | 126 |
| 2018 September | 61 | 20 | 81 |
| 2018 August | 2 | 0 | 2 |
| 2018 July | 3 | 0 | 3 |
| 2018 June | 4 | 0 | 4 |
| 2018 May | 5 | 0 | 5 |
| 2018 April | 25 | 0 | 25 |
| 2018 March | 32 | 0 | 32 |
| 2018 February | 21 | 0 | 21 |
| 2018 January | 20 | 0 | 20 |
| 2017 December | 18 | 0 | 18 |
| 2017 November | 20 | 0 | 20 |
| 2017 October | 28 | 0 | 28 |
| 2017 September | 27 | 0 | 27 |
| 2017 August | 20 | 0 | 20 |
| 2017 July | 29 | 2 | 31 |
| 2017 June | 37 | 28 | 65 |
| 2017 May | 31 | 15 | 46 |
| 2017 April | 41 | 36 | 77 |
| 2017 March | 19 | 11 | 30 |
| 2017 February | 18 | 9 | 27 |
| 2017 January | 12 | 7 | 19 |
| 2016 December | 29 | 27 | 56 |
| 2016 November | 35 | 27 | 62 |
| 2016 October | 29 | 18 | 47 |
| 2016 September | 39 | 9 | 48 |
| 2016 August | 51 | 10 | 61 |
| 2016 July | 37 | 25 | 62 |
Show all
